Investment case
Gilead Sciences, Inc.
GILD · 9 developments mapped · last assessed 2026-09-16
Market Ontology has mapped 9 macro, policy, and market developments to Gilead Sciences, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for GILD yet, so no modelled value is shown. The GILD valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run GILD on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook
Direct impact from new drug approval and increased sales guidance.
· Moves future revenue growth rates for hiv segment, market share in hiv treatment, profitability of new drug
- Open question
Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue Concentration
Increased competitive pressure for biotech acquisition targets, potential for higher acquisition premiums, or strategic response to LLY's diversification.
· Moves cost of m&a, strategic positioning in competitive landscape
What changed, by assumption
- 2026-09-02Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook
- 2026-09-02Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%
- 2026-09-02FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10%
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue Concentration
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-02 | Revenue | Bullish | FDA approval of Bixlenvo led to an upgrade in 2026 HIV franchise revenue growth guidance to 9-10%. | 0.95 |
| 2026-09-02 | Revenue | Bullish | FDA approval for Bixlenvo led to an upgrade in 2026 HIV franchise revenue growth projection to 9-10%. | 0.95 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Bullish | 1-5y | 0.70 |
| 2026-09-11 | GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff | watch | 3-12m | 0.30 |
| 2026-09-11 | GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff | watch | 1-3m | 0.30 |
| 2026-09-08 | Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue Concentration | watch | 3-12m | 0.40 |
| 2026-09-06 | Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand | Bullish | 1-5y | 0.40 |
| 2026-09-02 | Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook | Bullish | 3-12m | 0.80 |
| 2026-09-02 | Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10% | Bullish | 1-3m | 0.80 |
| 2026-09-02 | FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10% | Bullish | 1-3m | 0.80 |
| 2026-08-27 | Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch | watch | 3-12m | 0.20 |